In an evolving haemophilia landscape, therapeutic advancements are being made across all haemophilia subtypes, addressing unmet needs, especially in haemophilia with inhibitors. 

 This expert-led symposium will discuss:

•     The potential value of different classes of non-factor replacement therapy

•     Anti-TFPi as an emerging class of treatment

•     The effect of Concizumab prophylaxis on target joint resolution